Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
Corredor Endémico de Leptospirosis en Argentina
No full textEn el presente informe se muestra el corredor endémico de casos confirmados de leptospirosis notificados a SISA del primer y segundo trimestre del año 2020 (semanas 1 a 27).
Para la construcción del mismo se utilizó la información de los últimos 5 años, exceptuando al 2018 por ser un año de transición entre dos sistemas de vigilancia y de escasa cantidad de datos cargados. Por lo tanto, los años utilizados fueron 2014, 2015, 2016, 2017 y 2019. La información de los primeros cuatro años se obtuvo de SIVILA, mientras que la del año 2019 de SISA
Characterisation of ST25 NDM-1-producing Acinetobacter spp. strains leading the increase in NDM-1 emergence in Argentina
Get PDFFil: Rodgers, Deja. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Pasteran, Fernando. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Calderon, Manuel. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Jaber, Sara. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, California; Estados Unidos.Fil: Traglia, Germán M. Universidad de La República. Facultad de Medicina. Instituto de Higiene. Departamento de Desarrollo Biotecnología, Montevideo; Uruguay.Fil: Albornoz, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Antimicrobianos; Argentina.Fil: Vila, Alejandro J. Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET UNR), Rosario; Argentina.Fil: Bonomo, Robert A. Research Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio; Estados Unidos.Fil: Adams, Mark D. The Jackson Laboratory, Farmington, Connecticut; Estados Unidos.Fil: Ramírez, María Soledad. California State University Fullerton. College of Natural Sciences and Mathematics. Department of Biological Science. Center for Applied Biotechnology Studies, Fullerton, California; Estados Unidos
Lonomia envenomation in Brazil: an epidemiological overview for the period 2007-2018
No full textFil: Melo Favalesso, Marília. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Medicina Tropical; Argentina.Fil: Cuervo, Pablo Fernando. Laboratorio de Ecología de Enfermedades, Instituto de Ciencias Veterinarias del Litoral, Universidad Nacional del Litoral/Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Fil: Casafús, Milena Gisela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Medicina Tropical; Argentina.Fil: Bittencourt Guimaraes, Ana Tereza. Laboratório de Investigações Biológicas, Universidade Estadual do Oeste do Paraná; Brasil.Fil: Peichoto, Maria Elisa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Medicina Tropical; Argentina.Among the Lepidoptera with medical importance in Brazil, larvae of Lonomia moth (Saturniidae: Hemileucinae) stand out by being the etiological agent of the lonomism, a form of erucism in which the most troubling symptoms include systemic hemorrhage that can lead to death
Rapid Diagnostic Tests for Trypanosoma cruzi Infection: Field Evaluation of Two Registered Kits in a Region of Endemicity and a Region of Nonendemicity in Argentina
No full textFil: Lopez-Albizu, Constanza. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Danesi, Emmaría. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación de Endemo-Epidemias; ArgentinaFil: Piorno, Pablo. Asociación para Desarrollo Sanitario Regional (ADESAR); Argentina.Fil: Fernandez, Mariana. Asociación para Desarrollo Sanitario Regional (ADESAR); Argentina.Fil: García Campos, Francisco. Ministerio de Salud Pública de Salta; Argentina.Fil: Scollo, Karenina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Crudo, Favio. Asociación para Desarrollo Sanitario Regional (ADESAR); Argentina.Infection by Trypanosoma cruzi (Chagas disease [ChD]) affects around 7 million people in the Americas, most of whom are unaware of their status due to lack of clinical manifestations and poor access to diagnosis. Rapid diagnostic tests (RDTs) are widely used for screening for different infections (HIV, hepatitis B, and syphilis), and their application for ChD would facilitate access to diagnosis, especially in remote areas where health services have scarce resources. We conducted a prospective intervention study in 2018 to evaluate in the field two in vitro RDTs for ChD, authorized by the National Administration of Medicaments, Aliments, and Medical Technologies of Argentina (ANMAT), in areas of endemicity and nonendemicity in Argentina. We recruited 607 volunteers older than 18 years in Salta province and the city of Buenos Aires. The RDTs Ab Standard Diagnostics SD Bioline (SD) and Check Chagas Wiener Lab (WL) were performed in situ with whole-blood samples, and confirmatory serology was done at a reference center. The rate of infection with T. cruzi was 17.8% (108/607). The SD test showed 97.2% sensitivity (95% confidence interval [CI], 93.5 to 100) and 91.7% specificity (95% CI, 96.2 to 99.2%), and the WL test showed 93.4% sensitivity (95% CI, 88.2 to 98.6%) and 99.1% specificity (95% CI, 91.9 to 100%). The sensitivity and specificity for the two RDTs tested were higher than previously reported. These results encourage the use of the tested RDTs in Salta province and for further field studies for the implementation of these RDTs in other epidemiological scenarios. This will be very important to improve access to diagnosis of Chagas and its clinical management as a neglected disease, especially in remote areas with health access barriers
Simple phenotypic tests to improve accuracy in screening chromosomal and plasmid-mediated colistin resistance in gram-negative bacilli
Get PDFFil: Pasteran, Fernando. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Danze, Diego. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Menocal, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Cabrera, Carla. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Castillo, Ignacio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Albornoz, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Lucero, Celeste. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Rapoport, Melina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Ceriana, Paola. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.CLSI and EUCAST recommends that only broth microdilution (BMD) should be used for routine colistin susceptibility testing, however, it could be difficult to perform in resource-poor settings. The purpose of this study was to evaluate the accuracy of an agar spot test (COL-AS) and a colistin drop test (COL-DT) as compared to BMD. COL-AS and COL-DT were challenged with a collection of 271 Gram-negative bacilli clinical isolates: 195 Enterobacterales (including 63 mcr-1 positive strains), 37 Acinetobacter spp. and 39 Pseudomonas aeruginosa For COL-AS, 3.0μg/ml (final concentration) of colistin was added to a Mueller-Hinton agar plate and subsequently swabbed with a 0.5 McFarland suspension of tested strain within 1cm2 spot. For COL-DT, 10μl of a 16μg/ml colistin solution was dripped on the surface of a Mueller-Hinton agar plate, previously inoculated with a lawn of tested strain (0.5 McFarland). Colistin solution was made either, by dissolving powder or by disk elution in CA-MHB. Overall, 141/271 (52%) isolates were categorized as colistin resistant by reference BMD. COL-AS yielded a categorical agreement (CA) of 95.5% compared to BMD, with 0.7% very major errors and 3.8% major errors. COL-DT yielded a CA of 96.2% compared to BMD, with 0.7% and 0% very major errors and 3.1% and 3.8% major errors, for colistin powder and disk elution solutions, respectively. Most major errors occurred for mcr-1 producing strains with MICs that fluctuated from 2 to 4 μg/ml according to the method used. In conclusion, we developed and validated methods suited to the systematic screening of resistance to colistin in gram negative bacilli.Clinical relevance: colistin continues to be one of the last-line therapeutic options to treat carbapenemase-producing gram negative bacilli. The BMD reference methodology, recommended by current standards for evaluating colistin sensitivity, is difficult to implement in laboratories from low-resource countries. Recently CLSI endorsed two MIC-based alternative methods for testing colistin in Enterobacterales and P. aeruginosa, a colistin broth disk elution (CBDE) and a colistin agar test (CAT).In this work, we propose two simple methodologies, related to CLSI methods, to screen for colistin resistance, with a performance equivalent to the reference method in detecting resistance to colistin, both of plasmid (mcr) and chromosomal nature. Furthermore, the methods validated here allowed a better identification of those producers of mcr producer with borderline MICs. These screening tests can be routinely performed in addition to the tests currently in use, showed long stability during storage and some of them do not require colistin powder as the source of antibiotic, an important limitation in low-resource countries
Living with the COVID-19 pandemic: act now with the tools we have
Get PDFFil: Bedford, Juliet. Anthrologica, Oxfordshire; Reino Unido.Fil: Enria, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Giesecke, Johan. Karolinska Institute, Stockholm; Suecia.Fil: Heymann, David L. Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine; Reino Unido.Fil: Ihekweazu, Chikwe. Nigeria Centre for Disease Control; Nigeria.Fil: Kobinger, Gary. Infectious Disease Research Centre, Université Laval, Faculty of Medicine; Canada.Fil: Lane, H Clifford. National Institute of Allergy and Infectious Diseases; Estados Unidos.Fil: Memish, Ziad A. J W Lee Center for Global Medicine, SNU College of Medicine, Department of Internal Medicine, Seoul National University Hospital; Corea del Sur.Fil: Oh, Myoung-Don. J W Lee Center for Global Medicine, SNU College of Medicine, Department of Internal Medicine, Seoul National University Hospital; Corea del Sur.Fil: Sall, Amadou Alpha. Institut Pasteur de Dakar; Senegal.Fil: Ungchusak, Kumnuan. Ministry of Health, Department of Diseases Control; Tailandia.Fil: Wieler, Lothar H. Robert Koch Institute; Alemania.The responses of countries to the COVID-19 pandemic have been disparate.1, 2 Many countries are reopening workplaces, schools, and social gatherings and striving to adapt their economies and resume international travel. Other countries are attempting to suppress transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by again restricting businesses, industries, and schools while hoping for future COVID-19 vaccines or treatments. The Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH), the independent advisory group to the WHO Health Emergencies Programme, has reviewed information from countries around the world and has concluded that the most sound approach on the basis of current understanding is to deploy long-term strategies with a focus on preventing amplification of transmission, protecting those most at risk of severe illness, and supporting research to better understand the virus, the disease, and people's responses to them
Trypanosoma cruzi loop-mediated isothermal amplification (Trypanosoma cruzi Loopamp) kit for detection of congenital, acute and Chagas disease reactivation
Get PDFFil: Besuschio, Susana A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; ArgentinaFil: Picado, Albert. Foundation for Innovative New Diagnostics (FIND), Suiza.Fil: Muñoz-Calderón, Arturo. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; ArgentinaFil: Wehrendt, Diana P. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.Fil: Fernández, Marisa. Hospital de Enfermedades Infecciosas "Dr. Francisco J. Muñiz"; Argentina.Fil: Benatar, Alejandro. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.Fil: Diaz-Bello, Zoraida. Universidad Central de Venezuela, Caracas. Instituto de Medicina Tropical; Venezuela.Fil: Irurtia, Cecilia. Hospital Nacional "Profesor Alejandro Posadas"; Argentina.Fil: Cruz, Israel. Foundation for Innovative New Diagnostics (FIND); Suiza.Fil: Ndung'u, Joseph M. Foundation for Innovative New Diagnostics (FIND); Suiza.Fil: Cafferata, María L. Instituto de Efectividad Clínica y Sanitaria - Centro de Investigación en Epidemiología y Salud Pública. Departamento en Salud de la Madre y el Niño; Argentina.Fil: Montenegro, Graciela. Hospital Nacional "Profesor Alejandro Posadas"; Argentina.Fil: Sosa Estani, Sergio. ANLIS Dr. C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Lucero, Raúl H. Universidad Nacional de Nordeste. Instituto de Medicina Regional. Área de Biología Molecular; Resistencia, Argentina.Fil: Alarcón de Noya, Belkisyole. Universidad Central de Venezuela, Caracas. Instituto de Medicina Tropical; Venezuela.Fil: Longhi, Silvia A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor Torres". Laboratorio de Biología Molecular de la Enfermedad de Chagas; Argentina.A Trypanosoma cruzi Loopamp kit was recently developed as a ready-to-use diagnostic method requiring minimal laboratory facilities. We evaluated its diagnostic accuracy for detection of acute Chagas disease (CD) in different epidemiological and clinical scenarios. In this retrospective study, a convenience series of clinical samples (venous blood treated with EDTA or different stabilizer agents, heel-prick blood in filter paper or cerebrospinal fluid samples (CSF)) from 30 infants born to seropositive mothers (13 with congenital CD and 17 noninfected), four recipients of organs from CD donors, six orally-infected cases after consumption of contaminated guava juice and six CD patients coinfected with HIV at risk of CD reactivation (N = 46 patients, 46 blood samples and 1 CSF sample) were tested by T. cruzi Loopamp kit (Tc LAMP) and standardized quantitative real-time PCR (qPCR). T. cruzi Loopamp accuracy was estimated using the case definition in the different groups as a reference. Cohen's kappa coefficient (κ) was applied to measure the agreement between Tc LAMP (index test) and qPCR (reference test). Sensitivity and specificity of T. cruzi Loopamp kit in blood samples from the pooled clinical groups was 93% (95% CI: 77-99) and 100% (95% CI: 80-100) respectively. The agreement between Tc LAMP and qPCR was almost perfect (κ = 0.92, 95% CI: 0.62-1.00). The T. cruzi Loopamp kit was sensitive and specific for detection of T. cruzi infection. It was carried out from DNA extracted from peripheral blood samples (via frozen EDTA blood, guanidine hydrochloride-EDTA blood, DNAgard blood and dried blood spots), as well as in CSF specimens infected with TcI or TcII/V/VI parasite populations. The T. cruzi Loopamp kit appears potentially useful for rapid detection of T. cruzi infection in congenital, acute and CD reactivation due to HIV infection
Serosurvey of West Nile virus (WNV) in free-ranging raptors from Brazil
Get PDFFil: Morel, Ana Paula. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.Fil: Webster, Anelise. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.Fil: Zitelli, Larissa Calo. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.Fil: Umeno, Karen. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.Fil: Souza, Ugo Araújo. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.Fil: Prusch, Fabiane. Clinica Veterinária Toca dos Bichos, Porto Alegre, Río Grande del Sur; Brasil.Fil: Anicet, Marina. Clinica Veterinária Toca dos Bichos, Porto Alegre, Río Grande del Sur; Brasil.Fil: Marsicano, Gleide. Clinica Veterinária Toca dos Bichos, Porto Alegre, Río Grande del Sur; Brasil.Fil: Bandarra, Paulo. Nucleo de Reabilitação da Fauna Silvestre-UFPel, Pelotas, Río Grande del Sur; Brasil.Fil: Trainini, Gustavo. Hayabusa Consultoria Ambiental, São Francisco de Paula, Río Grande del Sur; Brasil.Fil: Stocker, Julian. Hayabusa Consultoria Ambiental, São Francisco de Paula, Río Grande del Sur; Brasil.Fil: Giani, Denise. Hayabusa Consultoria Ambiental, São Francisco de Paula, Río Grande del Sur; Brasil.Fil: Fortes, Flávia Borges. Secretaria da Agricultura Pecuária e Desenvolvimento Rural (SEAPDR). Programa Estadual de Sanidade Avícola (PESA), Porto Alegre, Río Grande del Sur; Brasil.Fil: Goenaga, Silvina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Reck, José. Instituto de Pesquisas Veterinárias Desidério Finamor (IPVDF). Centro de Pesquisa em Saúde Animal, Eldorado do Sul, Río Grande del Sur; Brasil.West Nile virus (WNV) is a mosquito-borne Flavivirus that can affect birds, horses, and humans, and is the only zoonotic Flavivirus that has been identified in six continents. In Brazil, until 2010, there was no evidence of WNV circulation. Recently, the virus was isolated from a horse with encephalitis, and the first human cases were registered in Brazil. Despite that, there is still no information on the enzootic cycle of this virus in birds or wildlife. This study aimed to investigate whether there is evidence of WNV circulation among wild birds from Southern Brazil. For this, we used free-living wild raptors (live-trapped or rescued) as potential sentinels to investigate the presence of WNV antibodies using ELISA and plaque reduction neutralization test (PRNT) assay. In addition, the presence of nucleic acids from Flavivirus family members was investigated. None of the birds sampled presented clinical findings compatible with WNV. Of the 200 serum samples from birds of prey belonging to 21 species, ten (5%) were positive for the presence of WNV antibodies on ELISA testing. The PRNT test did not confirm the ELISA results, but indicated that three birds had possibly been exposed to Saint Louis encephalitis virus (SLEV). All samples were negative for Flavivirus RNA. The results presented here evince the need for permanent surveillance for emerging flaviviruses in Brazil, as well as for a contingency policy in the case of human/animal outbreaks, particularly in high-risk areas